Literature DB >> 28044202

Cosmetic changes following surgery and accelerated partial breast irradiation using HDR interstitial brachytherapy : Evaluation by a multidisciplinary/multigender committee.

Tamer Soror1,2, György Kovács3, Nina Seibold3, Corinna Melchert3, Kristin Baumann4, Eike Wenzel5, Suzana Stojanovic-Rundic6.   

Abstract

BACKGROUND: Patients with early-stage breast cancer can benefit from adjuvant accelerated partial breast irradiation (APBI) following breast-conserving surgery (BCS). This work reports on cosmetic results following APBI using multicatheter high-dose-rate interstitial brachytherapy (HDR-IBT). PATIENTS AND METHODS: Between 2006 and 2014, 114 patients received adjuvant APBI using multicatheter HDR-IBT. For each patient, two photographs were analyzed: the first was taken after surgery (baseline image) and the second at the last follow-up visit. Cosmesis was assessed by a multigender multidisciplinary team using the Harvard Breast Cosmesis Scale. Dose-volume histogram (DVH) parameters and the observed cosmetic results were investigated for potential correlations.
RESULTS: The median follow-up period was 3.5 years (range 0.6-8.5 years). The final cosmetic scores were 30% excellent, 52% good, 14.5% fair, and 3.5% poor. Comparing the baseline and follow-up photographs, 59.6% of patients had the same score, 36% had a better final score, and 4.4% had a worse final score. Only lower target dose nonuniformity ratio (DNR) values (0.3 vs. 0.26; p = 0.009) were significantly associated with improved cosmetic outcome vs. same/worse cosmesis.
CONCLUSION: APBI using multicatheter HDR-IBT adjuvant to BCS results in favorable final cosmesis. Deterioration in breast cosmesis occurs in less than 5% of patients. The final breast cosmetic outcome in patients treated with BCS and APBI using multicatheter HDR-IBT is influenced primarily by the cosmetic result of the surgery. A lower DNR value is significantly associated with a better cosmetic outcome.

Entities:  

Keywords:  Breast cancer; Breast-conserving surgery; Photographs; Survival; Toxicity

Mesh:

Year:  2017        PMID: 28044202     DOI: 10.1007/s00066-016-1093-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  35 in total

1.  Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery.

Authors:  Vratislav Strnad; Jean-Michel Hannoun-Levi; Jose-Luis Guinot; Kristina Lössl; Daniela Kauer-Dorner; Alexandra Resch; György Kovács; Tibor Major; Erik Van Limbergen
Journal:  Radiother Oncol       Date:  2015-06-20       Impact factor: 6.280

2.  Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.

Authors:  Saskia Litière; Gustavo Werutsky; Ian S Fentiman; Emiel Rutgers; Marie-Rose Christiaens; Erik Van Limbergen; Margreet H A Baaijens; Jan Bogaerts; Harry Bartelink
Journal:  Lancet Oncol       Date:  2012-02-27       Impact factor: 41.316

3.  Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial.

Authors:  A J Khan; Douglas Arthur; F Vicini; P Beitsch; H Kuerer; S Goyal; Maureen Lyden; B G Haffty
Journal:  Ann Surg Oncol       Date:  2011-11-23       Impact factor: 5.344

4.  EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale.

Authors:  J J Pavy; J Denekamp; J Letschert; B Littbrand; F Mornex; J Bernier; D Gonzales-Gonzales; J C Horiot; M Bolla; H Bartelink
Journal:  Radiother Oncol       Date:  1995-04       Impact factor: 6.280

5.  Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.

Authors:  Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

6.  Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study.

Authors:  Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler
Journal:  Radiother Oncol       Date:  2010-02-22       Impact factor: 6.280

7.  Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery.

Authors:  Vratislav Strnad; Guido Hildebrandt; Richard Pötter; Josef Hammer; Marion Hindemith; Alexandra Resch; Kurt Spiegl; Michael Lotter; Wolfgang Uter; Mayada Bani; Rolf-Dieter Kortmann; Matthias W Beckmann; Rainer Fietkau; Oliver J Ott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

8.  Is oncoplastic surgery a contraindication for accelerated partial breast radiation using the interstitial multicatheter brachytherapy method?

Authors:  Anna-Maria Roth; Daniela Kauer-Dorner; Alexandra Resch; Andreas Schmid; Marc Thill; Peter Niehoff; Corinna Melchert; Daniel Berger; György Kovács
Journal:  Brachytherapy       Date:  2014 Jul-Aug       Impact factor: 2.362

9.  Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group.

Authors:  Jean-Michel Hannoun-Levi; Alexandra Resch; Jocelyn Gal; Daniela Kauer-Dorner; Vratislav Strnad; Peter Niehoff; Kristina Loessl; Gyoergy Kovács; Erick Van Limbergen; Csaba Polgár
Journal:  Radiother Oncol       Date:  2013-05-03       Impact factor: 6.280

10.  Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Authors:  Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

View more
  3 in total

1.  Aesthetic result after breast-conserving therapy is associated with quality of life several years after treatment. Swedish women evaluated with BCCT.core and BREAST-Q™.

Authors:  Cecilia Dahlbäck; Jenny Heiman Ullmark; Martin Rehn; Anita Ringberg; Jonas Manjer
Journal:  Breast Cancer Res Treat       Date:  2017-05-23       Impact factor: 4.872

2.  Multicatheter interstitial brachytherapy versus stereotactic radiotherapy with CyberKnife for accelerated partial breast irradiation: a comparative treatment planning study with respect to dosimetry of organs at risk.

Authors:  András Herein; Gábor Stelczer; Csilla Pesznyák; Georgina Fröhlich; Viktor Smanykó; Norbert Mészáros; Csaba Polgár; Tibor Major
Journal:  Radiol Oncol       Date:  2021-03-25       Impact factor: 2.991

3.  CyberKnife versus multicatheter interstitial brachytherapy for accelerated partial breast irradiation: a dosimetrical assessment with focus on organs at risk.

Authors:  András Herein; Gábor Stelczer; Csilla Pesznyák; Georgina Fröhlich; Viktor Smanykó; Norbert Mészáros; Csaba Polgár; Zoltán Takácsi-Nagy; Tibor Major
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.